Atezolizumab and bevacizumab-induced encephalitis in advanced hepatocellular carcinoma: Case report and literature review

INTRODUCTION: On the basis of the results of the IMBRAVE-150 trial, the combination of atezolizumab, a programmed cell death ligand 1 (PD-L1) antibody, as well as bevacizumab, a vascular endothelial growth factor (VEGF) antibody, represents a promising novel first-line therapy in patients with advan...

Descripción completa

Detalles Bibliográficos
Autores principales: Özdirik, Burcin, Jost-Brinkmann, Fabian, Savic, Lynn Jeanette, Mohr, Raphael, Tacke, Frank, Ploner, Christoph J., Roderburg, Christoph, Müller, Tobias
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2021
Materias:
5700
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8213300/
https://www.ncbi.nlm.nih.gov/pubmed/34128898
http://dx.doi.org/10.1097/MD.0000000000026377

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8213300/
https://www.ncbi.nlm.nih.gov/pubmed/34128898
http://dx.doi.org/10.1097/MD.0000000000026377

Ejemplares similares